摘要
目的分析20例胰腺癌及胰腺良性病变组织中miR-146a的表达差异,评价miR-146a在胰腺癌中表达的临床意义及其价值。方法收集笔者医院14例胰腺癌患者手术标本的癌组织,6例胰腺良性病变组织作为对照。采用Agilent人microRNA寡核苷酸基因芯片(V12.0)在基因组范围内检测20例组织标本的miR-146a表达,并分析其与胰腺癌临床病理参数的关系。结果胰腺癌组织中miR-146a的表达显著高于胰腺良性病变组织,差异有统计学意义(P=0.003),miR-146a在胰腺癌组织中的表达与患者年龄、性别、吸烟、临床分期、局部淋巴结转移,远处转移、CA199浓度、肿瘤分化程度、肿瘤分期,神经束膜侵犯、脉管侵犯均无相关性(P>0.05)。结论 miR-146a在胰腺癌的发生、发展过程可能发挥重要作用并可能成为胰腺癌新的肿瘤标记物或预后因子。
Objective To investigate the expression of miRNA-146a in the pancreatic cancer and pancreas benign lesions tissues and evaluate the clinical significance and applied value of miRNA-146a expression in pancreatic cancer. Methods Fourteen cases with pancreatic cancer were included in this study. The tissues were collected from every pancreatic cancer patient after pancreticoduodenectomy. Six pancreatic benign lesions tissues were used as controls. The Agilent Human miRNA Microarray （V12.0） was used to screen miR-146a different expression in the 20 samples, and its relationship with clinic pathological features was analyzed. Results The expression of miRNA-146a in pancreatic cancer was significantly higher than that in pancreatic benign lesions （P〈0.001）. There were no significant correlations between the expression of miRNA-146a and age, gender, smoking status, tumor stage, lymph node metastases, distant metastasis, tumor differentiation, nerve invasion, vessel invasion and the level of serum CA19-9 （P〉0.05）. Conclusions Upregatation of miR-146a in the pancreatic cancer suggests that it may be involved in tumourgenesis of panckeatic cancer, miR-146a may become a novel tumormarker or prognostic factor for pancreatic cancer.
出处
《岭南现代临床外科》
2013年第1期18-21,28,共5页
Lingnan Modern Clinics in Surgery
基金
卫生部卫生公益性行业科研专项经费项目(201202007)
广东省自然科学基金资助项目(2011010005036)
关键词
胰腺癌
MIR-146A
临床病理特征
Pancreatic cancer
microRNA- 146a
Clinicopathologic characteristics
